US Patent Issued to Circular Biotech on Feb. 17 for "Endogenous tumor-derived circular RNA and proteins thereof for use as vaccine" (Swedish Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,556, issued on Feb. 17, was assigned to Circular Biotech AB (Umea, Sweden).

"Endogenous tumor-derived circular RNA and proteins thereof for use as vaccine" was invented by Rolf Jonas Andreas Nilsson (Umea, Sweden) and Mattias Forsell (Umea, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an endogenous tumor-derived circular ribonucleic acid (circ RNA) as well as one or more proteins expressed from said tumor-derived circ RNA. The invention further relates said tumor-derived circ RNA and the protein(s) expressed thereof for use vaccines in the prophylaxis and/or treatment of cancer."

The patent was filed on Dec...